Previous 10 | Next 10 |
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2020 financial results and provide a corporate update on Tuesday, February 23, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session via confer...
High-scoring, high short-interest stocks that can benefit from ongoing short covering by hedge funds as they reduce single stock risk. Institutional quality stocks with potential catalysts that support ongoing short covering, rather than flash-in-the-pan volatility. Ideas across a...
Arena Pharma (ARNA) announces that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate receptor modulator, in participants with moderately-to-severely active...
– Evaluating 2 mg etrasimod in study participants with moderately-to-severely active ulcerative colitis (UC) – Topline data from ELEVATE UC 12 and UC 52 trials remain on track for Q1 2022 – Significant unmet need for safe and effective oral therapi...
Arena Pharmaceuticals, Inc. (ARNA) 39th Annual J.P. Morgan Healthcare Conference January 13, 2021 01:00 PM ET Company Participants Amit Munshi - President and Chief Executive Officer Conference Call Participants Jess Fye - JP Morgan Presentation Jess Fye Good morning everyone. My name is Jess...
After a steep drop in November, Arena Pharmaceuticals (ARNA) is optimistic about 2021, due to its upcoming clinical trials. Arena Pharmaceuticals Inc. ( ARNA ) is a San Diego-headquartered biopharmaceutical company that develops novel medicines with pharmacology and phar...
Arena stock is trading at a discount to its early November highs of $88, at $75.5 at time of writing. The value is mostly in Etrasimod - a new type of treatment for immune related diseases such as Ulcerative Colitis, Crohn's Disease, and Atopic Dermatitis. Shares dropped in Novemb...
Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13 PR Newswire SAN DIEGO , Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chie...
22nd Century Group (XXII) has been on an incredible run since receiving a new U.S. patent for breakthrough technology that helps reduce nicotine in tobacco plants. Read ahead to find out if XXII can continue its momentum. The company is awaiting imminent authorization of its MRTP (Modified Ri...
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference SAN DIEGO , Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b AD...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...